James Stocklaser Who said BUY ACAD, Now Says CELG is STRONG BUY. ((link))
Seeking: James Stocklaser Who said BUY ACAD, Now Says CELG is STRONG BUY. ((link))
A Reasoned Case For Celsion's ThermoDox
December 10, 2012 BY:
James Stocklasar Thomas Jr
I think it's common knowledge that any therapy that promotes progression free recurrence is a global billion dollar plus market opportunity. As others have pointed out, with ThermoDox targeting multiple medical indications, the long-term market opportunity is a billion dollar multiple. Seeing how Celsion has already extended the ThermoDox footprint into the European and Asia markets along with the rest of the world including the United States, I hesitate to imagine how high on phase III success the company's share price could rise as events unfold. Therefore, priced in the $7's/share and taking every risk into account, I conclude based on my three-prong study that Celsion is a VERY STRONG BUY.